As the dust settles on Cures, what will it mean for biopharma R&D?

PHIL TAYLOR | December 22, 2016

article image
At almost 1,000 pages, the 21st Century Cures Act is quite literally a weighty piece of legislation that will have far-reaching consequences for pharma in 2017 and beyond. After months of political wrangling, Cures was eventually signed into law by President Obama as his term in office was drawing to a close, and provides $4.8 billion for three of his administration's flagship projects: Vice President Joe Biden's cancer moonshot, the BRAIN Initiative, and the Precision Medicine Initiative. Another $1 billion is earmarked to fight the opioid epidemic, and the FDA gets an extra $500 million.

Spotlight

BRDG Park

The Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center offers leading bio-research facilities with world-class wet labs, office space for lease and on-site workforce training. Emerging scientific enterprises get just the right combination for success – interactions between top scientists and access to state-of-the-art core facilities such as technologically advanced greenhouses, growth chambers, microscopy, proteomics and tissue transformation facilities, as well as other vital resources.

OTHER ARTICLES

2 Small-Cap Biotech Stocks You Haven't Heard of, But Should Know About

Article | April 17, 2020

With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks that aren't actively involved in developing tests, vaccines or treatments for COVID-19. Vaccine developers, protective equipment producers, and healthcare service providers are all attracting plenty of attention during this pandemic, but there are just as many promising biotech stocks that aren't involved in these areas. Here are two such companies that you might have missed, but they deserve a spot on your watch list.

Read More

Ruminating on Bioprocessing 4.0

Article | February 18, 2020

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Wisconsin biotech companies could play key roles in long-term economic recovery from COVID-19 pandemic

Article | April 19, 2020

Whether it’s called a modern “Manhattan Project” or a medical moon shot, the concept of long-term economic recovery rests on how confident people are they won’t risk serious illness by venturing forth in public again. Wisconsin stands to be a significant part of such an undertaking, whatever it’s called. The shorter-term debate is well under way over the gradual lifting of COVID-19 emergency rules, such as the now-extended “safer-at-home” order in Wisconsin. At least a dozen states, including regional coalitions on the East and West coasts, are exploring next steps as they seek to balance responses to the virus with calls for reopening the economy, at least, in part. Wisconsin’s ability to shape longer-term responses will come from private and public resources, which range from companies engaged in production of diagnostics.

Read More

Pfizer, BioNTech Plan Clinical Trial for COVID-19 mRNA Vaccine Candidate

Article | April 9, 2020

Pfizer and BioNTech plan to begin human clinical trials on their lead COVID-19 therapeutic candidate, an mRNA vaccine, by the end of this month, the companies said today, through a collaboration that could generate up to $748 million for the German biotech. The companies announced plans last month to partner on BNT162, the first treatment to emerge from BioNTech’s accelerated COVID-19-focused development program, “Project Lightspeed.” BioNTech and Pfizer established collaboration intended to draw upon BioNTech’s proprietary mRNA vaccine platforms, and Pfizer’s expertise in vaccine research and development, regulatory capabilities, and global manufacturing and distribution network.

Read More

Spotlight

BRDG Park

The Bio Research & Development Growth (BRDG) Park at the Danforth Plant Science Center offers leading bio-research facilities with world-class wet labs, office space for lease and on-site workforce training. Emerging scientific enterprises get just the right combination for success – interactions between top scientists and access to state-of-the-art core facilities such as technologically advanced greenhouses, growth chambers, microscopy, proteomics and tissue transformation facilities, as well as other vital resources.

Events